Helium is in short supply. MRI machines remain stubbornly enormous. And that, in compressed form, is the challenge facing hospitals trying to expand diagnostic imaging.
The longer version involves geopolitical disruptions halfway around the world, multimillion-dollar scanners trapped in purpose-built suites, and an upstart company asking a deceptively simple question: What if high-quality MRI could fit in a trailer parked outside a clinic?
Adialante, a Spring 2026 Y Combinator alum spun out of the University of Minnesota, believes it has cracked the code. The company holds two issued U.S. patents for radiofrequency-based spatial encoding techniques that, according to its founders, reduce MRI hardware size by half and slash system weight by 80 percent. Those aren't modest claims. If they hold up under real-world scrutiny, they'd represent something closer to a paradigm shift in how these machines get designed and where they can go.
The timing, too, feels almost scripted. In March and April of last year, disruptions to helium production facilities in Qatar—roughly 30 percent of the world's supply vanished overnight, with repairs expected to take years. Conventional MRI scanners depend on liquid helium to cool their superconducting magnets, and the sudden scarcity sent shockwaves through hospital procurement offices already wrestling with seven-figure equipment budgets and construction timelines that stretch across seasons.
The Technical Wager
At the heart of Adialante's pitch is a departure from traditional gradient coils in favor of RF encoding. The patents—issued in July 2025 and May 2026, assigned to the Regents of the University of Minnesota—describe methods for spatial localization using frequency-modulated RF pulses. Efraín Torres, who co-invented the technology during his biomedical engineering PhD at Minnesota, now serves as CEO. The university named him Student Entrepreneur of the Year in 2023, a nod to his early momentum.
The company says its system draws 60 percent less power and runs "whisper-quiet," specifications that matter when you're trying to install imaging equipment in outpatient clinics rather than reinforced hospital wings. Traditional MRI installations are exercises in structural engineering: RF-shielded rooms, reinforced floors capable of bearing tons of weight, quench pipes for emergency helium venting, HVAC retrofits. Industry figures peg room construction alone at $350,000 to north of $1 million—before the scanner itself, which can run $1.2 million to $3 million for a standard 1.5 Tesla system.
There's a reason most MRI machines live in basements or ground-floor bunkers. Adialante wants to change that calculus entirely.
The stated goal is diagnostic-grade image quality matching conventional systems, delivered in a mobile unit that requires zero infrastructure build-out. No independent, peer-reviewed validation of those performance claims has surfaced publicly yet. Which is, of course, the gap every medical device investor knows to watch.
Starting Small: Prostate Imaging
The go-to-market strategy hinges on pre-biopsy prostate MRI for urology clinics—a deliberately narrow wedge. The American Urological Association and Society of Urologic Oncology conditionally recommended multiparametric MRI before initial biopsy in their 2023 guidelines, citing improved detection of clinically significant cancer and fewer unnecessary biopsies. A November 2023 study in JAMA Network Open suggested annual MRI with potential MRI-guided biopsy could meet U.S. payer cost-effectiveness thresholds for men with PSA levels above 2.5 ng/mL.
Payer policies have begun catching up. Aetna's clinical policy bulletin, updated in March 2026, deems MRI-guided prostate biopsy and MRI-TRUS fusion medically necessary when specific criteria are met. Blue Cross Blue Shield of Mississippi outlined similar indications in a January 2025 update. The reimbursement pathways exist. The question is whether Adialante can execute operationally.
The company reports securing $12.75 million in letters of intent and $30,000 in deposits from six clinics, including what it describes as a top-10 urology group. According to Adialante, its first system was expected to be scanning by demo day. These figures come directly from the company and haven't been independently confirmed.
The business model sidesteps the capital purchase problem: Adialante owns and operates scanners housed in mobile trailers, charging clinics on a per-scan basis. Clinics don't buy equipment. They don't build rooms. They book scanning days. It echoes the established mobile MRI rental market—companies like Shared Medical Services have run GE wide-bore fleets for years, cycling capacity across hospitals and outpatient centers. Adialante's angle is pairing that service model with proprietary hardware designed from scratch for portability.
Mobile Imaging Isn't New—But Lighter Could Be Different
Mobile MRI has been around for decades. Michigan's Department of Health tracked mobile route utilization data through 2024. In June of last year, the U.K.'s InHealth Group announced plans to purchase 10 new Siemens scanners for its mobile fleet, aiming to cut NHS wait times. Seven Corners Healthcare launched mobile services targeting rural and underserved communities in May 2025.
But those are conventional systems in oversized trailers. An 80 percent weight reduction, if real, changes the math. Lighter equipment theoretically means easier transport, lower operating costs, simpler logistics. Whether that translates to unit economics that pencil out at scale—well, that remains to be demonstrated.
Adialante's roadmap fans out beyond prostate. Plans include musculoskeletal imaging for orthopedics, breast screening, renal studies, brain scans. Breast MRI is particularly intriguing. Blue Cross of North Carolina removed prior authorization requirements for breast MRI in dense breast populations effective January 2025. Demand is expanding while access stays constrained.
Whole-body MRI screening sits further out on the risk curve. Prenuvo raised $120 million in February 2025 to expand its direct-to-consumer centers, but the American College of Radiology issued a cautious statement in April 2023, noting insufficient evidence to recommend total-body screening MRI for asymptomatic individuals. The clinical utility debate grinds on.
Helium's Sudden Scarcity
The 2026 helium supply shock wasn't Adialante's creation, but it reframes the competitive landscape. Major manufacturers have been inching toward helium-sparing designs for years. Philips' BlueSeal systems, which seal roughly seven liters of helium for the machine's lifetime and eliminate quench pipes, surpassed 1,000 global installations by March 2024. Siemens Healthineers markets DryCool sealed-for-life magnets across platforms, including its 0.55T MAGNETOM Free.Max, which contains just 0.7 liters of helium.
Those are still conventional gradient-based architectures, though. They reduce helium dependency but don't eliminate the hardware's sheer bulk. When repair timelines for Qatar's production facilities stretch to "three to five years"—as multiple industry analyses from March through May 2026 suggested—hospitals face operational risk on existing fleets and difficult capital allocation decisions on new purchases.
Adialante's RF encoding approach, if it delivers as advertised, sidesteps the helium problem differently: by fundamentally shrinking the hardware footprint that requires cooling in the first place. That's the pitch, anyway. It's also the hypothesis awaiting validation in clinical practice.
The company raised $1.18 million through an NSF SBIR Phase II grant announced in September 2025. Add a $10,000 grand prize from the University of Minnesota's Walleye Tank competition in December 2023 and acceptance into Y Combinator's Spring 2026 batch, and you have a collection of early validation signals. But funding from programs and accelerators isn't the same as clinical evidence or deployed systems generating revenue. Not even close.
The Unproven Variables
Medical device commercialization is a game of checkpoints. Adialante has two issued patents and NSF backing. What it doesn't have publicly: FDA clearance, peer-reviewed imaging studies, head-to-head comparisons against 1.5T or 3T reference standards, or demonstrated per-scan economics.
MRI systems fall under FDA Class II, product code LNH. Novel encoding techniques might still achieve 510(k) clearance by demonstrating substantial equivalence to existing devices—but a fundamentally different technical approach could require a de novo pathway. The regulatory strategy shapes both timeline and risk profile.
Clinical validation will demand comparative reader studies. For prostate imaging, that means PI-RADS scoring, sensitivity and specificity for clinically significant cancer, biopsy correlation. Radiologists and urologists will want those numbers before routing patient volume to an unproven platform. Payers will want real-world cost and utilization data before building coverage policy around a new entrant.
The team was listed at four members at the time of Y Combinator acceptance, though the company's website later identified additional roles, including principal software and systems engineers with relevant academic credentials. Parker Jenkins, co-founder and COO, provides operational partnership to Torres' technical leadership.
Cancer's Demand Curve
The market backdrop is undeniable. The World Health Organization and International Agency for Research on Cancer projected 35 million new cancer cases annually by 2050, a 77 percent increase from 20 million in 2022. Early detection remains the most powerful lever for improving survival outcomes. The American Cancer Society's 2026 report, released in January, underscored stage-dependent survival disparities across cancer types. Access to imaging correlates with outcomes, sometimes starkly.
Whether Adialante's technology can deliver diagnostic-quality scans, navigate regulatory approval, secure payer contracts, and operate profitably at per-scan pricing—that's the story still being written. The company says its first system would be scanning soon. That's when physics meets healthcare operations. When claims become data.
For now, it's a wager on RF encoding, mobile deployment, and reimbursed cancer pathways in a market suddenly attuned to helium scarcity and capital efficiency. The patents are real. The letters of intent are reported. The clinical validation is pending.
That's the current state of play for a startup trying to bring MRI out of the basement and into the clinic parking lot. Whether it succeeds or stumbles will depend less on the elegance of the engineering and more on the messy realities of healthcare economics, regulatory timelines, and whether radiologists trust what they see on the screen. No amount of Y Combinator polish can shortcut that process.
